Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Gastroenterology · Gastroesophageal Junction Cancer

What Is the Siewert Classification for Esophageal Cancer?

At a Glance

The Siewert classification identifies whether a gastroesophageal junction tumor is centered in the lower esophagus, at the junction, or in the upper stomach. It helps guide surgical planning, but TNM staging and tumor biology determine the broader treatment plan.

When your doctor mentions a “Siewert type” for your tumor, they are referring to a classification system used to map where a cancer is centered at the gastroesophageal junction (GEJ)—the area where the esophagus (the swallowing tube) meets the stomach. This classification is primarily used for adenocarcinomas (cancers that start in glandular cells), which are the most common tumors at this junction [1]. Because this junction is a border between two organs, knowing precisely where the center (epicenter) of the tumor is located helps the surgical team estimate whether they will need to remove part of the esophagus, part or all of the stomach, or both [2].

What This Classification Does Not Tell You

While the Siewert type describes location, it does not tell your doctor your cancer’s stage (how deeply it has grown or if it has spread to lymph nodes or other organs) or your exact treatment plan. Your treatment relies on TNM staging—using endoscopic ultrasound, CT, or PET-CT scans—and your tumor’s biology [3][4]. Depending on the clinical stage, your multidisciplinary team (a group of different specialists working together) may recommend chemotherapy or chemoradiation before surgery to shrink the tumor, rather than proceeding directly to an operation [3][5].

How the Siewert Types are Measured

The Siewert classification divides tumors into three types based on the location of the tumor’s epicenter relative to the anatomic GEJ, which doctors identify during an endoscopy by looking for the top of the gastric (stomach) folds [6]. It is important to note that this is different from the Z-line, which is where the color of the inner lining visibly changes. In patients with conditions like Barrett’s esophagus, the Z-line can shift upward, so doctors use the true anatomic GEJ to define the Siewert type [6][2].

  • Siewert Type I: The tumor’s center is located 1 to 5 centimeters above the anatomic GEJ. This means the cancer is primarily in the lower esophagus [2][7].
  • Siewert Type II: The tumor’s center is located within a transition zone right at the junction—from 1 centimeter above the GEJ to 2 centimeters below it [7][8]. This is often called a “true carcinoma of the cardia” (the cardia is the uppermost part of the stomach).
  • Siewert Type III: The tumor’s center is located 2 to 5 centimeters below the GEJ. This cancer is situated primarily in the upper part of the stomach and extends upward toward the junction [2][7].

How Siewert Type Informs Surgery

When surgery is appropriate and the tumor is resectable (able to be removed), the primary surgical goal is an R0 resection. This means the tumor is removed with clear, cancer-free tissue at its borders (margins) under a microscope [9]. An R0 resection is the surgical goal for the best outcome, though it does not guarantee that microscopic cancer cells haven’t spread elsewhere. The Siewert type acts as a starting point for surgical planning, though your surgeon will also consider tumor extension, lymph node risk (requiring lymphadenectomy, or lymph node removal), and your overall fitness [10].

  • For Type I Tumors: Because these are essentially esophageal cancers, surgeons typically perform an esophagectomy. This involves removing the affected portion of the esophagus and the topmost part of the stomach. To reconstruct your digestive tract, the surgeon will often reshape the remaining stomach into a new tube to reconnect your swallowing path, although sometimes the colon or small intestine is used if the stomach is not suitable [11].
  • For Type III Tumors: These are generally treated following gastric (stomach) cancer principles. The surgeon will remove either the upper part of the stomach (proximal gastrectomy) or the entire stomach (total gastrectomy), along with a small portion of the lowest part of the esophagus [12][13]. The choice between proximal and total gastrectomy is not interchangeable; it depends heavily on the tumor’s size, margins, and lymph node involvement [14].
  • For Type II Tumors: Because these tumors sit directly on the border, there is no single standard operation. The surgical approach must be highly individualized [2][10]. Your surgical team might choose an esophagectomy or an extended gastrectomy depending on how far the tumor invades into the esophagus or stomach, which lymph node basins are at risk, and your personal health factors [10][12][9].

Reconstruction after these surgeries can bring significant lifestyle changes, including smaller and more frequent meals, acid reflux, altered bowel habits, or a temporary feeding tube. Receiving a cancer diagnosis and preparing for these changes is frightening, which is why meeting with a specialist dietitian before and after surgery is a critical part of adapting and optimizing your nutrition.

Common questions in this guide

What is the Siewert classification used for in esophageal cancer?
The Siewert classification describes where a tumor is centered in relation to the gastroesophageal junction, where the esophagus meets the stomach. It is used mainly for adenocarcinomas at this junction and helps the surgical team plan the operation.
How are Siewert types I, II, and III different?
Type I is centered 1 to 5 centimeters above the gastroesophageal junction, in the lower esophagus. Type II is centered from 1 centimeter above to 2 centimeters below the junction. Type III is centered 2 to 5 centimeters below the junction, in the upper stomach.
Does a Siewert type tell me what stage my cancer is?
No. The Siewert type describes location, not how deeply the cancer has grown or whether it has spread. Doctors assess stage using the TNM system, imaging and other tests such as endoscopic ultrasound, CT, or PET-CT, together with tumor biology.
Why is the true anatomic gastroesophageal junction important?
Doctors identify the true anatomic junction during endoscopy by looking for the top of the stomach folds. This is different from the Z-line, which marks a visible color change in the lining; in Barrett’s esophagus, the Z-line can shift upward and may not accurately show the junction.
What surgery is usually considered for each Siewert type?
When surgery is appropriate, Type I tumors are usually treated with an esophagectomy, while Type III tumors generally follow stomach cancer surgery principles with a proximal or total gastrectomy. Type II tumors have no single standard operation, so the team may consider an esophagectomy or an extended gastrectomy based on tumor extension, lymph node risk, and overall health.
Will I need chemotherapy or chemoradiation before surgery?
Possibly, but the answer depends on the cancer’s clinical stage, tumor biology, whether it can be removed, and your overall health. A multidisciplinary team may recommend chemotherapy or chemoradiation before surgery to shrink the tumor rather than operating first.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my TNM stage and histology, and does the Siewert classification apply to my specific tumor?
  2. 2.Did the endoscopy clearly identify the true anatomic gastroesophageal junction separate from the Z-line when finding the tumor's epicenter?
  3. 3.Based on my tumor's location and stage, will I need chemotherapy or chemoradiation before surgery?
  4. 4.What are the benefits and risks of an esophagectomy versus a gastrectomy for my specific tumor?
  5. 5.How many gastroesophageal junction operations does this team perform, and what is the plan if pathology shows involved margins?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer.

    Hoeppner J, Brunner T, Schmoor C, et al.

    The New England journal of medicine 2025; (392(4)):323-335 doi:10.1056/NEJMoa2409408.

    PMID: 39842010
  2. 2

    Optimal management of gastroesophageal junction cancer.

    Greally M, Agarwal R, Ilson DH

    Cancer 2019; (125(12)):1990-2001 doi:10.1002/cncr.32066.

    PMID: 30973648
  3. 3

    Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).

    Zhou HY, Zheng SP, Li AL, et al.

    EClinicalMedicine 2020; (24()):100422 doi:10.1016/j.eclinm.2020.100422.

    PMID: 32637899
  4. 4

    Genomic Landscape of Adenocarcinomas Across the Gastroesophageal Junction: Moving on From the Siewert Classification.

    Nakauchi M, Walch HS, Nussenzweig S, et al.

    Annals of surgery 2025; (281(6)):989-996 doi:10.1097/SLA.0000000000006363.

    PMID: 38841851
  5. 5

    Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review.

    Mukherji R, Alqahtani A, Yin C, et al.

    Journal of thoracic disease 2023; (15(6)):3466-3487 doi:10.21037/jtd-23-27.

    PMID: 37426147
  6. 6

    Global variations in diagnostic guidelines for Barrett's esophagus.

    Kusano C, Singh R, Lee YY, et al.

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2022; (34(7)):1320-1328 doi:10.1111/den.14342.

    PMID: 35475586
  7. 7

    True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.

    Kumamoto T, Kurahashi Y, Niwa H, et al.

    Surgery today 2020; (50(8)):809-814 doi:10.1007/s00595-019-01843-4.

    PMID: 31278583
  8. 8

    Considering the esophagogastric junction as a 'zone'.

    Ichihara S, Uedo N, Gotoda T

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2017; (29 Suppl 2()):3-10 doi:10.1111/den.12792.

    PMID: 28425656
  9. 9

    Surgical approach to advanced Siewert II cancer: beyond the borders? The West Side.

    Hölscher AH, Bollschweiler E, Fetzner UK, Babic B

    Updates in surgery 2023; (75(2)):329-333 doi:10.1007/s13304-022-01363-w.

    PMID: 36001282
  10. 10

    Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type II, and Nishi types EG, E=G and GE cancers.

    Hölscher AH, Law S

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2020; (23(1)):3-9 doi:10.1007/s10120-019-01022-x.

    PMID: 31691875
  11. 11

    Supradiaphragmatic Roux-en-Y jejunal reconstruction after extended total gastrectomy for gastroesophageal adenocarcinoma.

    Sewell M, Sihag S, Bott MJ, et al.

    JTCVS techniques 2025; (33()):247-255 doi:10.1016/j.xjtc.2025.05.020.

    PMID: 41112448
  12. 12

    Open left diaphragm method enables safe surgery with a good visual field in a laparoscopic transhiatal approach for esophagogastric junction adenocarcinoma laparoscopic transhiatal reconstruction via an open left diaphragm method.

    Kanaji S, Urakawa N, Harada H, et al.

    Langenbeck's archives of surgery 2024; (409(1)):174 doi:10.1007/s00423-024-03359-z.

    PMID: 38837064
  13. 13

    Survival Benefit of Pyloric Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Based on Tumor Diameter: A Large Cohort Study.

    Lin X, Li Z, Tan C, et al.

    Frontiers in oncology 2021; (11()):748694 doi:10.3389/fonc.2021.748694.

    PMID: 34926257
  14. 14

    Comparative study of laparoscopic-assisted and open total gastrectomy for Siewert Types II and III adenocarcinoma of the esophagogastric junction.

    Wang J, Wang JC, Song B, et al.

    Journal of cellular physiology 2019; (234(7)):11235-11239 doi:10.1002/jcp.27777.

    PMID: 30478913

This page is for informational purposes only and does not constitute medical advice. Your gastroenterologist and surgical oncology team must interpret your tumor’s location and stage and recommend the right treatment for you.

Get notified when new evidence is published on Carcinoma of esophagus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.